Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-12-23Clinical Trial Update: Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia [Phase 4]
A Phase 4 randomized study comparing paliperidone extended-release with risperidone in schizophrenia to assess neurocognitive function; the …
-
FDA approval · 2011-12-21FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Fluphenazine Decanoate by Mylan Institutional LLC, updating the labeling for this long-acting in…
-
CLINICAL_TRIALS trial_result · 2011-12-16Clinical Trial Update: The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia [Phase 4]
A completed Phase 4 clinical trial evaluating minocycline for negative and cognitive symptoms in schizophrenia.
-
CLINICAL_TRIALS trial_result · 2011-12-14Clinical Trial Update: Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
A completed AstraZeneca study investigates how patient characteristics influence the therapeutic effects of atypical antipsychotics, includi…
-
CLINICAL_TRIALS research · 2011-12-13Clinical Trial Update: A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia [Phase 4]
Phase 4 double-blind, placebo-controlled trial evaluating donepezil as adjunctive treatment for cognitive impairment in schizophrenia. Curre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-12-02Clinical Trial Update: Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode [Phase 4]
This Phase 4 clinical trial reports results for a long-acting injectable form of risperidone in patients with schizophrenia after an acute e…
-
FDA approval · 2011-11-30FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Mylan Institutional LLC)
FDA granted a supplemental approval for HALOPERIDOL DECANOATE by Mylan Institutional LLC. This relates to an approved generic long-acting an…
-
FDA approval · 2011-11-29FDA Approved: RISPERIDONE — Original Application (Solco Healthcare US, LLC)
The FDA approved the original application for a generic risperidone manufactured by Solco Healthcare US, LLC. The approval covers standard i…
-
FDA approval · 2011-11-28FDA Approved: RISPERIDONE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for a generic risperidone product from Amneal Pharmaceuticals NY LLC under ANDA 078071.
-
CLINICAL_TRIALS trial_result · 2011-11-24Clinical Trial Update: Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective Study
A completed prospective study evaluating infant development after in utero exposure to antipsychotics in pregnancies of women with schizophr…
-
CLINICAL_TRIALS trial_result · 2011-11-23Clinical Trial Update: Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness [Phase 3]
Phase 3 trial assessing the impact of genetic counseling for female first-degree relatives of individuals with schizophrenia, bipolar disord…
-
CLINICAL_TRIALS trial_result · 2011-11-23Clinical Trial Update: Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) [Phase 4]
Phase 4 clinical trial update assessing the efficacy and safety of quetiapine fumarate extended-release (Seroquel XR) in schizophrenia; resu…
-
CLINICAL_TRIALS research · 2011-11-23Clinical Trial Update: Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea
This clinical trial update reports on the prevalence of metabolic syndrome among patients with schizophrenia in Korea.
-
CLINICAL_TRIALS trial_result · 2011-11-18Clinical Trial Update: Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia [NA]
This terminated clinical trial evaluated aggressive treatment of metabolic syndrome in patients with schizophrenia who are receiving clozapi…
-
FDA approval · 2011-11-15FDA Approved: RISPERIDONE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for risperidone by Chartwell RX, LLC, related to the generic product's labeling.
-
FDA approval · 2011-11-15FDA Approved: RISPERIDONE — Supplemental Application (Westminster Pharmaceuticals, LLC)
FDA approves Westminster Pharmaceuticals' supplemental application for risperidone (generic), updating its approved status under an ANDA.
-
CLINICAL_TRIALS trial_result · 2011-11-11Clinical Trial Update: Quetiapine XR in Schizophrenic Patients [Phase 3]
A Phase 3 trial of quetiapine XR for schizophrenia was terminated.
-
FDA approval · 2011-11-10FDA Approved: RISPERIDONE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic risperidone product from Aurobindo Pharma Limited.
-
FDA approval · 2011-11-09FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental application for SEROQUEL (quetiapine) from H2-Pharma, LLC.
-
FDA approval · 2011-11-09FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA has approved a supplemental application for SEROQUEL XR (quetiapine) by AstraZeneca Pharmaceuticals LP. The approval pertains to mod…
-
FDA approval · 2011-11-08FDA Approved: RISPERIDONE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application to approve a generic risperidone product from Amneal Pharmaceuticals LLC under ANDA 091384.
-
CLINICAL_TRIALS trial_result · 2011-11-07Clinical Trial Update: Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)
This document reports a completed clinical trial evaluating a point-of-care hematological monitoring device (CHEMPAQ) for clozapine safety i…
-
FDA approval · 2011-11-04FDA Approved: RISPERIDONE — Original Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approved Jubilant Cadista's generic risperidone under an Original Application (ANDA 090839).
-
CLINICAL_TRIALS trial_result · 2011-11-01Clinical Trial Update: The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics [Phase 1]
A Phase 1 study evaluated AZD8529 for effects on cognition and negative symptoms in people with schizophrenia. The trial has been completed.
-
CLINICAL_TRIALS research · 2011-11-01Clinical Trial Update: Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression
An observational study sponsored by AstraZeneca that completed and examined bipolar disorder symptoms in patients with schizophrenia, schizo…